Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 315

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

Open access
McMillin, Douglas W, Delmore, Jake, Weisberg, Ellen, Negri, Joseph M, Geer, D Corey, Klippel, Steffen, Mitsiades, Nicholas, Schlossman, Robert L, Munshi, Nikhil C, Kung, Andrew L, Griffin, James D, Richardson, Paul G, Anderson, Kenneth C, Mitsiades, Constantine S·2010·Nature Medicine

Abstract

Conventional anticancer drug screening is typically performed in the absence of accessory cells of the tumor microenvironment, which can profoundly alter antitumor drug activity. To address this limitation, we developed the tumor cell–specific in vitro bioluminescence imaging (CS-BLI) assay. Tumor cells (for example, myeloma, leukemia and solid tumors) stably expressing luciferase are cultured with nonmalignant accessory cells (for example, stromal cells) for selective quantification of tumor cell viability, in presence versus absence of stromal cells or drug treatment. CS-BLI is high-throughput scalable and identifies stroma-induced chemoresistance in diverse malignancies, including imatinib resistance in leukemic cells. A stroma-induced signature in tumor cells correlates with adverse clinical prognosis and includes signatures for activated Akt, Ras, NF-κB, HIF-1α, myc, hTERT and IRF4; for biological aggressiveness; and for self-renewal. Unlike conventional screening, CS-BLI can also identify agents with increased activity against tumor cells interacting with stroma. One such compound, reversine, shows more potent activity in an orthotopic model of diffuse myeloma bone lesions than in conventional subcutaneous xenografts. Use of CS-BLI, therefore, enables refined screening of candidate anticancer agents to enrich preclinical pipelines with potential therapeutics that overcome stroma-mediated drug resistance and can act in a synthetic lethal manner in the context of tumor-stroma interactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.2112

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 315

Metadata

Authors
McMillin, D. W., Delmore, J., Weisberg, E., Negri, J. M., Geer, D. C., Klippel, S., Mitsiades, N., Schlossman, R. L., Munshi, N. C., Kung, A. L., Griffin, J. D., Richardson, P. G., Anderson, K. C., & Mitsiades, C. S.
Venue
Nature Medicine
Published
2010-03-14
Volume
16
Issue
4
Pages
483-489
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2049150145
Cited by
315
References
38
FWCI
13.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. https://app.cochat.ai/papers/10.1038/nm.2112
The paper
McMillin, D. W., Delmore, J., Weisberg, E., Negri, J. M., Geer, D. C., Klippel, S., Mitsiades, N., Schlossman, R. L., Munshi, N. C., Kung, A. L., Griffin, J. D., Richardson, P. G., Anderson, K. C., & Mitsiades, C. S. (2010). Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nature Medicine. https://doi.org/10.1038/nm.2112

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.